News & Updates

Use of tumour necrosis factor inhibitor (TNFi) does not appear to contribute to incident hypertension in individuals with ankylosing spondylitis (AS), reports a study.

Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) who have been initiated on apalutamide in a real-world setting appear to show prostate-specific antigen (PSA) response that is strong and consistent with that reported in clinical trials, as reported in a study.

Treatment with sotrovimab reduces the risk of all-cause hospitalization or death in patients with COVID-19 who are at high risk of progression to severe disease, regardless of anti-SARS-CoV-2 serostatus, according to a study presented at CROI 2022.

Treatment with the novel EGFR tyrosine kinase inhibitors (EGFR-TKI) abivertinib at 300 mg twice a day appears to be effective in patients with EGFR T790M-positive nonsmall cell lung cancer (NSCLC), while having manageable side effects, according to the results of a phase II trial.

Most patients with inflammatory bowel disease (IBD) build an initial immune response to SARS-CoV-2 vaccination, but older patients, those treated with antitumour necrosis factor (anti-TNF) and an immunomodulator, and those on corticosteroids may require an additional vaccine dose to achieve better immunity against COVID-19, according to a study.

Use of oral antibiotics in the treatment of osteomyelitis, bacteraemia, and infective endocarditis results in shorter hospital stay, has a better safety profile, and appears to be similarly effective when compared to intravenous (IV)-only therapy, a recent study has shown.

Rescue therapy using the Janus kinase 1 inhibitor abrocitinib combined with topical medicated therapy recaptured efficacy responses and had a favourable safety profile in individuals with moderate-to-severe atopic dermatitis (AD) who experienced flare during the maintenance period of the phase III randomized-withdrawal JADE REGIMEN trial.

Treatment with intravenous brivaracetam is well tolerated in children with epilepsy, with a safety profile consistent with that known of the oral formulation, according to the results of a phase II study. There has been no pharmacokinetic difference observed when administered as bolus or a 15-minute infusion.